```
     (FILE 'HOME' ENTERED AT 07:40:32 ON 13 MAR 2006)

     FILE 'CAPLUS' ENTERED AT 07:40:41 ON 13 MAR 2006
L1            46 S SPINA?(L)PRODRUG?
L2             0 S L1 AND (CNS(L)(SIDE(W)EFFEC?))
L3             5 S L1 AND CNS

=> s l1 not l3
L4            41 L1 NOT L3

=> s l4 and (side(w)effec?)
        509325 SIDE
       6547937 EFFEC?
         51514 SIDE(W)EFFEC?
L5             1 L4 AND (SIDE(W)EFFEC?)

=> d bib hit

L5   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2003:950045  CAPLUS
DN   140:770
TI   Administration of acetylcholinesterase inhibitors via intranasal delivery
     to the cerebral spinal fluid for treatment of cognitive disorders
IN   Quay, Steven C.
PA   USA
SO   U.S. Pat. Appl. Publ., 23 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   US 2003225031        A1    20031204    US 2003-439108          20030515
     CA 2482161           AA    20040108    CA 2003-2482161         20030519
     WO 2004002402        A2    20040108    WO 2003-US15653         20030519
     WO 2004002402        A3    20041007
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1505971           A2    20050216    EP 2003-751761          20030519
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005532372        T2    20051027    JP 2004-517563          20030519
     US 2004254146        A1    20041216    US 2004-831031          20040423
     US 2006003989        A1    20060105    US 2005-112950          20050422
PRAI US 2002-382122P      P     20020521
     US 2003-439108       A2    20030515
     WO 2003-US15653      W     20030519
     US 2004-831031       A2    20040423
AB   Methods and compns. are disclosed that provide acetylcholinesterase
     inhibitors for the prevention and treatment of diseases and disorders of
     the central nervous system, including dementia such as Alzheimer's
     disease, to the central nervous system via intranasal delivery.  The
     methods and compns. of the present invention provide therapeutic concns.
     of the acetylcholinesterase inhibitor in the cerebrospinal fluid of a
     mammal without the attendant disadvantages, risks and side
```

effects of oral or injection delivery.

IT Drug delivery systems
(**prodrugs**; administration of acetylcholinesterase inhibitors via intranasal delivery to the cerebral **spinal** fluid for treatment of cognitive disorders)

```
=> s spina?(l)prodrug?
         82625 SPINA?
         14754 PRODRUG?
L1          46 SPINA?(L)PRODRUG?

=> s l1 and (cns(l)(side(w)effec?))
         35248 CNS
        509325 SIDE
       6547937 EFFEC?
           502 CNS(L)(SIDE(W)EFFEC?)
L2           0 L1 AND (CNS(L)(SIDE(W)EFFEC?))

=> s l1 and cns
         35248 CNS
L3           5 L1 AND CNS

=> d bib hit 5

L3   ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   1999:763302  CAPLUS
DN   132:73529
TI   Propofol hemisuccinate protects neuronal cells from oxidative injury
AU   Sagara, Yutaka; Hendler, Sheldon; Khoh-Reiter, Sue; Gillenwater, Gail;
     Carlo, Dennis; Schubert, David; Chang, Jennie
CS   Salk Institute for Biological Studies, La Jolla, CA, 92037, USA
SO   Journal of Neurochemistry (1999), 73(6), 2524-2530
     CODEN: JONRA9; ISSN: 0022-3042
PB   Lippincott Williams & Wilkins
DT   Journal
LA   English
RE.CNT  58    THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB   Oxidative stress contributes to the neuronal death observed in
     neurodegenerative disorders and neurotrauma.  Some antioxidants for
     CNS injuries, however, have yet to show mitigating effects in
     clin. trials, possibly due to the impermeability of antioxidants across
     the blood-brain barrier (BBB).  Propofol (2,6-diisopropylphenol), the
     active ingredient of a commonly used anesthetic, acts as an antioxidant,
     but it is insol. in water.  Therefore, we synthesized its water-soluble
     prodrug, propofol hemisuccinate sodium salt (PHS), and tested for its
     protective efficacy in neuronal death caused by non-receptor-mediated,
     oxidative glutamate toxicity.  Glutamate induces apoptotic death in rat
     cortical neurons and the mouse hippocampal cell line HT-22 by blocking
     cystine uptake and causing the depletion of intracellular glutathione,
     resulting in the accumulation of reactive oxygen species (ROS).  PHS has
     minimal toxicity and protects both cortical neurons and HT-22 cells from
     glutamate.  The mechanism of protection is attributable to the
     antioxidative property of PHS because PHS decreases the ROS accumulation
     caused by glutamate.  Furthermore, PHS protects HT-22 cells from oxidative
     injury induced by homocysteic acid, buthionine sulfoximine, and hydrogen
     peroxide.  For comparison, we also tested α-tocopherol succinate
     (TS) and methylprednisolone succinate (MPS) in the glutamate assay.
     Although TS is protective against glutamate at lower concns. than PHS, TS
     is toxic to HT-22 cells.  In contrast, MPS is nontoxic but also
     nonprotective against glutamate.  Taken together, PHS, a water-soluble
     prodrug of propofol, is a candidate drug to treat CNS injuries
     owing to its antioxidative properties, low toxicity, and permeability
     across the BBB.
IT   Spinal cord
        (injury; propofol prodrug propofol hemisuccinate protects
        neuronal cells from oxidative injury)
```

=> d bib hit 1-4

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:550943 CAPLUS
DN 141:106492
TI Preparation of pyrimidine derivatives for the treatment of abnormal cell growth in cancer
IN Kath, John Charles; Luzzio, Michael Joseph
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056786	A2	20040708	WO 2003-IB6055	20031217
	WO 2004056786	A3	20041021		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004220177	A1	20041104	US 2003-734039	20031211
	CA 2510848	AA	20040708	CA 2003-2510848	20031217
	AU 2003288603	A1	20040714	AU 2003-288603	20031217
	EP 1578732	A2	20050928	EP 2003-780443	20031217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003017435	A	20051116	BR 2003-17435	20031217
	NL 1025071	A1	20040622	NL 2003-1025071	20031218
	NL 1025071	C2	20041230		
PRAI	US 2002-435670P	P	20021220		
	WO 2003-IB6055	W	20031217		

OS MARPAT 141:106492
AB The title compds. [I; wherein R1 = Q1; wherein D = independently (un)substituted CH or N, with the proviso that R1 is linked to NH group through a ring carbon atom; wherein E, G = N, C; X, W, Q = N, O, S, SO2, CO, NR3, CR2, CR2R3; Y and Z are independently present or absent, if present, Y, Z = N, O, S, SO2, CO, NR3, CR2 and CR2R3; wherein A is present or absent, if present, A = O, S, NH; B is present or absent, if present, B = CO, SO2, or NR6, with the proviso that when A is O or S and B is absent; n = an integer from 1-3; R2 = H, C1-6 alkyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, O-C1-6 alkyl, O-C3-7 cycloalkyl, O-C4-7 heterocycloalkyl, NH2, NHR6, NR6R7, SR6, SOR6, SO2R6, CO2R6, CONH2, CONHR6, CONR6R7, SO2NH2, SO2NHR6, SO2NR6R7, NHCOR6, NR6CONR6, NHCONHR, NR6CONHR, NHCONR6R7, NR6CONR6R7, NHSO2R6, NR6SO2R6, etc.; R3 = H, C1-6 alkyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, CO2R6, CONH2, CONHR5, CONR6R7 or CR2R3 taken together can form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring; R4 = H, C1-6 alkyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, etc.; R5 = H, Br, Cl, cyano, CF3, CH2F, CHF2, SO2Me, CONH2, cyclopropyl, cyclobutyl, Ph, CONHR6, CONR6R7, CO2R6, etc.; R6, R7 = group listed in R3] or pharmaceutically acceptable salts, **prodrugs** and solvates thereof are prepared These compds. are selective inhibitors of non-receptor FAK protein tyrosine kinase (no data). The invention also relates to methods of treating abnormal cell growth, in particular cancer, in mammals by administering the compds. I and to pharmaceutical compns. containing the compds. I for treating such disorders. The said cancer is selected from

lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, col on cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (**CNS**), primary **CNS** lymphoma, **spinal** axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. Thus, N-(5-Bromo-2-chloropyrimidin-4-yl)-N-(p-tolyl)amine was aminatred with 4-(5-Amino-1H-indol-3-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-Bu ester in the presence of triethylamine in dioxane at 100° for 16 h to give 4-[5-[5-Bromo-4-(p-tolylamino)pyrimidin-2-ylamino]-1H-indol-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-Bu ester which was treated with HCl in a mixture of MeOH and dioxane at room temperature for 6 h to give 5-Bromo-N2-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N4-(p-tolyl)pyrimidine-2,4-diamine hydrochloride.

IT Central nervous system, disease
(primary **CNS** lymphoma; preparation of pyrimidine derivs. as selective inhibitors of non-receptor tyrosine kinase for treatment of abnormal cell growth, in particular cancers)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:851122 CAPLUS
DN 135:371759
TI Preparation of N-imidazolylphenyl-5,6-dihydrobenzo[h]quinazolin-4-amines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of **CNS** disorders
IN Yamada, Akira; Spears, Glen; Hayashida, Hisashi; Tomishima, Masaki; Ito, Kiyotaka; Imanishi, Masashi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087845	A2	20011122	WO 2001-JP4002	20010514
	WO 2001087845	A3	20020829		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001056728	A5	20011126	AU 2001-56728	20010514
	US 2003176454	A1	20030918	US 2002-258582	20021101
PRAI	AU 2000-7501	A	20000515		
	AU 2000-1955	A	20001207		
	WO 2001-JP4002	W	20010514		

OS MARPAT 135:371759
TI Preparation of N-imidazolylphenyl-5,6-dihydrobenzo[h]quinazolin-4-amines and other N-containing heterocyclic amines as 5-hydroxytryptamine

antagonists for treatment of CNS disorders

AB Title compds. AMQNHZ [I; wherein A = H, (un)substituted, unsatd., N-containing heterocyclic group, or C(NH)NHR; R = (un)substituted aryl or heterocyclic group; M = (CH2)n, (CH2)nO(CH2)m, or (CH2)nNH(CH2)m; n and m = independently 0-2; Q = (un)substituted cycloalkylene group, arylene, or divalent heterocyclic group; Z = (un)substituted, unsatd., mono-, di-, tri-, or tetra-cyclic, N-containing heterocyclic group which may contain addnl. N, O, and S atoms as the ring member(s), e.g. indeno[1,2,3-de]phthalazinyl or 5,6-dihydrobenzo[h]quinazolinyl; and the prodrugs or pharmaceutically acceptable salts thereof] were prepared For example, a mixture of 4-chloro-5,6-dihydrobenzo[h]quinazoline, 3-(1,2-dimethyl-1H-imidazol-5-yl)aniline, and 1,3-dimethyl-2-imidazolidinone was heated for an hour at 200°C, cooled, treated with 1N aqueous NaOH and water, and worked up to give II. I are 5-hydroxytryptamine (5-HT) antagonists useful for the prevention and/or treatment of central nervous system (CNS) disorders, such as anxiety, depression, obsessive compulsive disorders, migraine, anorexia, Alzheimer's disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse, schizophrenia, and disorders associated with spinal trauma and/or head injury (no data).

IT Drugs of abuse
(abuse of, treatment of withdrawal; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT Appetite
(anorexia nervosa, treatment; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT Appetite
(bulimia, treatment; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT Sleep
(disorder, treatment; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT Head
(injury, treatment; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT Mental disorder
(obsession-compulsion, treatment; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT Anxiety
(panic disorder, treatment; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT Anti-Alzheimer's agents
Antidepressants
Antimigraine agents
Anxiolytics
Nervous system agents
(preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT Spinal cord

(trauma, treatment; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT Schizophrenia
(treatment; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT 1673-30-9P 3435-26-5P, 4-Chloro-6-phenylpyrimidine 19571-30-3P, 4-Phenylisoquinoline 21977-72-0P, 2-[(Dimethylamino)methylene]cycloheptanone 32003-14-8P 34551-41-2P, 1-Chloro-5-bromoisoquinoline 36999-81-2P, Indeno[1,2,3-de]phthalazin-3(2H)-one 40848-53-1P, 1-Benzyl-4-chlorophthalazine 56913-94-1P, N-(3-Nitrophenyl)-N'-(2-pyridylmethyl)thiourea 65810-96-0P, 1-Chloro-4-phenylisoquinoline 65811-00-9P, 4-Phenylisoquinoline-2-oxide 112101-60-7P, Methyl 4-oxo-4,5,6,7-tetrahydro-1-benzothiophene-5-carboxylate 114686-05-4P, Methyl 7-oxo-4,5,6,7-tetrahydro-1-benzothiophene-6-carboxylate 127056-45-5P, tert-Butyldimethylsilyl 1H-imidazol-4-ylmethyl ether 134722-25-1P, 5,6-Dihydro[1]benzoxepino[5,4-d]pyrimidin-4-ol 134722-26-2P, 4-Chloro-5,6-dihydro[1]benzoxepino[5,4-d]pyrimidine 213837-41-3P, 1-[(Dimethylamino)methylene]-1,3-dihydro-2H-inden-2-one 223671-17-8P, 5-Bromoisoquinoline-2-oxide 223671-29-2P, 1-Chloro-5-phenylisoquinoline 361548-81-4P, 3-(1,2-Dimethyl-1H-imidazol-5-yl)-5-methoxyaniline 361550-34-7P 361551-64-6P, 3-(1,2-Dimethyl-1H-imidazol-5-yl)-5-fluoroaniline 374554-24-2P, (3-Nitrophenyl)(5-phenylisoquinolin-1-yl)amine 374554-25-3P, (3-Aminophenyl)(5-phenylisoquinolin-1-yl)amine 374554-27-5P, [3-(5-Phenylisoquinolin-1-ylamino)benzyl]carbamic acid benzyl ester 374554-28-6P, (3-Aminomethylphenyl)(5-phenylisoquinolin-1-yl)amine 374554-29-7P, 5-(Thiophen-3-yl)isoquinoline 374554-30-0P, 5-(Thiophen-3-yl)isoquinoline 2-oxide 374554-31-1P, 1-Chloro-5-(thiophen-3-yl)isoquinoline 374554-32-2P, (5-Bromoisoquinolin-1-yl)(3-nitrophenyl)amine 374554-33-3P, (3-Aminophenyl)(5-bromoisoquinolin-1-yl)amine 374554-34-4P, (3-Nitrophenyl)(isoquinolin-1-yl)amine 374554-35-5P, (3-Aminophenyl)(isoquinolin-1-yl)amine 374554-36-6P, 5-(4-Fluorophenyl)isoquinoline 374554-37-7P, 5-(4-Fluorophenyl)isoquinoline-2-oxide 374554-38-8P, 1-Chloro-5-(4-fluorophenyl)isoquinoline 374554-40-2P, N-(Benzo[d]isoxazol-3-yl)benzene-1,3-diamine 374554-45-7P, 3-Bromo-2-fluoro-N-hydroxy-N'-(3-nitrophenyl)benzamidine 374554-47-9P, (7-Bromobenzo[d]isoxazol-3-yl)(3-nitrophenyl)amine 374554-49-1P, (3-Nitrophenyl)-(7-phenylbenzo[d]isoxazol-3-yl)amine 374554-50-4P, N-(7-Phenylbenzo[d]isoxazol-3-yl)benzene-1,3-diamine 374554-52-6P, N-(7-Bromobenzo[d]isoxazol-3-yl)benzene-1,3-diamine 374554-56-0P, 1-Chloro-5-(pyrrol-1-yl)isoquinoline 374554-58-2P, 1-[3-(Quinolin-2-ylamino)phenyl]ethanone 374554-59-3P, 2-Bromo-1-[3-(quinolin-2-ylamino)phenyl]ethanone 374554-60-6P 374554-61-7P 374554-62-8P 374554-63-9P 374554-64-0P, 5,6-Dihydrothieno[2,3-h]quinazolin-4-ol 374554-65-1P, 4-Chloro-5,6-dihydrothieno[2,3-h]quinazoline 374554-66-2P, 5,6-Dihydrothieno[3,2-h]quinazolin-4-ol 374554-67-3P, 4-Chloro-5,6-dihydrothieno[3,2-h]quinazoline 374554-68-4P, [3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl]thiourea 374554-69-5P, 1-Benzoyl-3-[3-(4,5-dimethylimidazol-1-yl)phenyl]thiourea 374554-71-9P, [6-(2-Methylpyridin-3-yloxy)pyridin-3-yl]thiourea 374554-72-0P 374554-73-1P 374554-74-2P 374554-75-3P, 4-Chloro-6-(thiophen-2-yl)pyrimidine 374554-76-4P 374554-78-6P, N-[3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl]guanidine dihydrochloride 374554-80-0P, 9-Methoxy-5,6-dihydrobenzo[h]quinazolin-4-ol 374554-81-1P, 4-Chloro-9-methoxy-5,6-dihydrobenzo[h]quinazoline 374554-82-2P, 9-Methyl-4,5-dihydro[1]benzoxepino[5,4-c]isoxazol-3-ol 374554-83-3P 374554-84-4P, 4,5-Dihydro[1]benzoxepino[5,4-c]isoxazol-3-amine 374554-85-5P, 1-Bromo-3-(1,2-dimethylimidazol-5-yl)benzene 374554-86-6P, N-Formyl-3-(imidazol-1-yl)aniline 374554-87-7P, N-[3-(Imidazol-1-yl)phenyl]-N-(5-nitropyridin-2-yl)formamide 374554-88-8P,

N-[3-(Imidazol-1-yl)phenyl]-N-[5-(pyrrol-1-yl)pyridin-2-yl]formamide 374554-90-2P, 5-Chloro-N-(6-fluorobenzo[d]isoxazol-3-yl)benzene-1,3-diamine 374554-91-3P, 5-Chloro-N-(6-chlorobenzothiazol-2-yl)benzene-1,3-diamine 374554-92-4P 374554-93-5P, 3-Bromo-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2-fluorobenzamide 374554-94-6P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-2-fluoro-3-(3-thienyl)benzamide 374554-95-7P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-2-fluoro-3-(2-thienyl)benzamide 374554-96-8P, 3-Bromo-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2-fluoro-N'-hydroxybenzenecarboximidamide 374554-97-9P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-2-fluoro-N'-hydroxy-3-(2-thienyl)benzenecarboximidamide 374554-98-0P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-2-fluoro-N'-hydroxy-3-(3-thienyl)benzenecarboximidamide 374554-99-1P, 3-Bromo-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2-fluorobenzenecarbohydrazonamide 374555-00-7P, Methyl 2-fluoro-3-(2-thienyl)benzoate 374555-01-8P, Methyl 2-fluoro-3-(3-thienyl)benzoate 374555-02-9P, 2-Fluoro-3-(2-thienyl)benzoic acid 374555-03-0P, 2-Fluoro-3-(3-thienyl)benzoic acid 374555-04-1P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-N'-(2-pyridylmethyl)thiourea 374555-05-2P, N-[[3-Chloro-5-(trifluoromethyl)-2-pyridyl]methyl]-N'-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]thiourea 374555-06-3P, 3-[(3-Nitrophenyl)amino]imidazo[1,5-a]pyridine 374555-07-4P 374555-08-5P, 8-(2-Thienyl)-4-quinazolinol 374555-09-6P, 1-Chloro-4-(4-fluorobenzyl)phthalazine 374555-10-9P, 4-Benzyl-1-chloroisoquinoline 374555-11-0P, 4-(2-Thienylmethyl)isoquinoline 374555-13-2P, 1-Chloro-4-(2-thienylmethyl)isoquinoline 374555-14-3P, 7-(3-Thienyl)-1H-indole-2,3-dione 374555-15-4P, 2-Amino-3-(3-thienyl)benzoic acid 374555-17-6P, 4-Chloro-8-(3-thienyl)quinazoline 374555-18-7P, Methyl 7-fluoro-1-oxo-1,2,3,4-tetrahydro-2-naphthalenecarboxylate 374555-19-8P, 9-Fluoro-5,6-dihydrobenzo[h]quinazolin-4-ol 374555-20-1P, 4-[[(tert-Butyldimethylsilyl)oxy]methyl]-1-(3-nitrophenyl)-1H-imidazole 374555-21-2P, 3-[4-[[(tert-Butyldimethylsilyl)oxy]methyl]-1H-imidazol-1-yl]aniline 374555-96-1P, 3-(4,5-Dimethylimidazol-1-yl)phenylthiourea 384340-98-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT 374556-66-8P, N-[3-[4-[[[tert-Butyldimethylsilyl]oxy]methyl]-1H-imidazol-1-yl]phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT 374555-22-3P, N-[3-(5-Phenylisoquinolin-1-ylamino)phenyl]benzamidine 374555-23-4P, 4-Fluoro-N-[3-(5-phenylisoquinolin-1-ylamino)phenyl]benzamidine 374555-24-5P, [6-(2-Methylpyridin-3-yloxy)pyridin-3-yl](5-phenylisoquinolin-1-yl)amine 374555-25-6P, (3-Imidazol-1-ylphenyl)(5-phenylisoquinolin-1-yl)amine 374555-26-7P, [3-[(1H-Benzimidazol-2-ylamino)methyl]phenyl](5-phenylisoquinolin-1-yl)amine 374555-27-8P, [3-[(1-Methyl-1H-benzimidazol-2-ylamino)methyl]phenyl](5-phenylisoquinolin-1-yl)amine 374555-28-9P, [3-(Imidazol-1-yl)phenyl][5-(thiophen-3-yl)isoquinolin-1-yl]amine 374555-29-0P, [3-(Pyrimidin-5-yl)phenyl][5-(thiophen-3-yl)isoquinolin-1-yl]amine 374555-30-3P, [5-(Thiophen-3-yl)isoquinolin-1-yl]-[3-([1,2,4]triazol-1-yl)phenyl]amine 374555-31-4P, [3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl][5-(thiophen-3-yl)isoquinolin-1-yl]amine 374555-32-5P, [6-(2-Methylpyridin-3-yloxy)pyridin-3-yl](5-thiophen-3-ylisoquinolin-1-yl)amine 374555-33-6P, [4-Methyl-3-(pyrimidin-5-

yl)phenyl][5-(thiophen-3-yl)isoquinolin-1-yl]amine 374555-34-7P, (5-Bromoisoquinolin-1-yl)[3-(imidazol-1-yl)phenyl]amine 374555-35-8P, (5-Bromoisoquinolin-1-yl)[3-(2,3-dimethyl-3H-imidazol-4-yl)phenyl]amine 374555-36-9P, [3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl][5-(4-fluorophenyl)isoquinolin-1-yl]amine 374555-37-0P, (5-Bromoisoquinolin-1-yl)[3-(pyrimidin-5-yl)phenyl]amine 374555-38-1P, N-[3-(5-Bromoisoquinolin-1-ylamino)phenyl]benzamidine 374555-40-5P, (5-Bromoisoquinolin-1-yl)[6-(2-methylpyridin-3-yloxy)pyridin-3-yl]amine 374555-41-6P, (Isoquinolin-1-yl)[6-(2-methylpyridin-3-yloxy)pyridin-3-yl]amine 374555-42-7P, N-[3-(Isoquinolin-1-ylamino)phenyl]benzamidine 374555-43-8P, [3-(Imidazol-1-yl)phenyl](4-phenylisoquinolin-1-yl)amine 374555-44-9P, [3-(Imidazol-1-yl)phenyl][5-(4-fluorophenyl)isoquinolin-1-yl]amine 374555-45-0P, N-[3-(Benzo[d]isoxazol-3-ylamino)phenyl]benzamidine 374555-46-1P 374555-47-2P, N-[3-(Benzo[d]isoxazol-3-ylamino)phenyl]benzamidine methanesulfonate 374555-48-3P, N-[3-(Benzo[d]isoxazol-3-ylamino)phenyl]thiophene-2-carboxamidine 374555-49-4P, N-[3-(7-Phenylbenzo[d]isoxazol-3-ylamino)phenyl]benzamidine 374555-50-7P, N-[3-[(7-Bromobenzo[d]isoxazol-3-yl)amino]phenyl]benzamidine 374555-51-8P, (Benzo[d]isoxazol-3-yl)[6-(2-methylpyridin-3-yloxy)pyridin-3-yl]amine 374555-52-9P, [5-(Pyrrol-1-yl)isoquinolin-1-yl]-[3-([1,2,4]triazol-1-yl)phenyl]amine 374555-53-0P, [3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl][5-(pyrrol-1-yl)isoquinolin-1-yl]amine 374555-54-1P, [6-(2-Methylpyridin-3-yloxy)pyridin-3-yl][5-(pyrrol-1-yl)isoquinolin-1-yl]amine 374555-55-2P, [4-Methyl-3-(pyrimidin-5-yl)phenyl][5-(pyrrol-1-yl)isoquinolin-1-yl]amine 374555-56-3P, [3-(1-Methylimidazol-5-yl)phenyl](quinolin-2-yl)amine 374555-57-4P, [3-(1-Methylimidazol-5-yl)phenyl](isoquinolin-1-yl)amine 374555-58-5P, (4-Benzylphthalazin-1-yl)(3-imidazol-1-ylphenyl)amine 374555-59-6P, N,N'-Di(isoquinolin-1-yl)butane-1,4-diamine 374555-60-9P, N,N'-Di(isoquinolin-1-yl)-trans-cyclohexane-1,4-diamine 374555-61-0P, (Indeno[1,2,3-de]phthalazin-3-yl)[3-(imidazol-1-yl)phenyl]amine 374555-62-1P, (Indeno[1,2,3-de]phthalazin-3-yl)[3-(isoquinolin-1-ylaminomethyl)phenyl]amine 374555-63-2P, N-[3-(Indeno[1,2,3-de]phthalazin-3-ylamino)phenyl]benzamidine hydroiodide 374555-64-3P, (Indeno[1,2,3-de]phthalazin-3-yl)[3-(2,3-dimethyl-3H-imidazol-4-yl)phenyl]amine 374555-65-4P, [Indeno[1,2,3-de]phthalazin-3-yl][3-(1-methylimidazol-5-yl)phenyl]amine 374555-66-5P, [3-(Imidazol-1-yl)phenyl](isoquinolin-1-yl)amine 374555-67-6P, [3-(Imidazol-1-yl)phenyl](phthalazin-1-yl)amine 374555-68-7P, N-(Indeno[1,2,3-de]phthalazin-3-yl)-N'-(isoquinolin-1-yl)butane-1,4-diamine 374555-69-8P, N-[3-Chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374555-70-1P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)-5-fluorophenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374555-71-2P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374555-72-3P, N-[3-(4,5-Dimethyl-1H-imidazol-1-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374555-73-4P, 3-Chloro-N5-[5,6-dihydrobenzo[h]quinazolin-4-yl]-N2-(2-pyridylmethyl)-2,5-pyridinediamine 374555-74-5P, N-[6-[(2-Methyl-3-pyridyl)oxy]-3-pyridyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374555-75-6P, N-[3-(4-Methyl-1H-imidazol-1-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374555-76-7P, N-[3-(1H-1,2,4-Triazol-1-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374555-77-8P, N-[3-(5-Pyrimidinyl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374555-78-9P, N-[4-Methyl-3-(5-pyrimidinyl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374555-79-0P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-5,6-dihydrothieno[2,3-h]quinazolin-4-amine 374555-80-3P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-5,6-dihydrothieno[3,2-h]quinazolin-4-amine 374555-81-4P, N-[3-(4,5-Dimethyl-1H-imidazol-1-yl)phenyl]-5,6-dihydrothieno[2,3-h]quinazolin-4-amine 374555-83-6P, [4-(5-Chloro-2-methoxyphenyl)thiazol-2-yl][3-(imidazol-1-yl)phenyl]amine 374555-84-7P, [4-(5-Chloro-2-methoxyphenyl)thiazol-2-yl][3-(imidazol-1-yl)phenyl]amine hydrobromide 374555-85-8P, [4-(2-Chlorophenyl)thiazol-2-yl][3-(imidazol-1-yl)phenyl]amine 374555-86-9P, [4-(4-Chlorophenyl)thiazol-2-yl][3-

(imidazol-1-yl)phenyl]amine 374555-87-0P, [4-(3-Chlorophenyl)thiazol-2-yl][3-(imidazol-1-yl)phenyl]amine 374555-88-1P, [4-(5-Chlorothiophen-2-yl)thiazol-2-yl][3-(imidazol-1-yl)phenyl]amine 374555-89-2P, [3-(Imidazol-1-yl)phenyl](5-phenylthiazol-2-yl)amine 374555-90-5P, (4-Phenylthiazol-2-yl)[3-(imidazol-1-yl)phenyl]amine 374555-91-6P, [3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl](5-phenylthiazol-2-yl)amine 374555-92-7P, (4,5-Dihydronaphtho[2,1-d]thiazol-2-yl)[3-(2,3-dimethyl-3H-imidazol-4-yl)phenyl]amine 374555-93-8P, [3-(4,5-Dimethylimidazol-1-yl)phenyl](5-phenylthiazol-2-yl)amine 374555-95-0P, [3-(4,5-Dimethylimidazol-1-yl)phenyl][5-(2-methoxyphenyl)thiazol-2-yl]amine 374555-97-2P, (4,5-Dihydronaphtho[2,1-d]thiazol-2-yl)[3-(4,5-dimethylimidazol-1-yl)phenyl]amine 374555-98-3P, N-[3-(4,5-Dimethyl-1H-imidazol-1-yl)phenyl]-N-[4H-indeno[2,1-d][1,3]thiazol-2-yl]amine 374555-99-4P, N-[6-(2-Methylpyridin-3-yloxy)pyridin-3-yl]-N-[4H-indeno[2,1-d][1,3]thiazol-2-yl]amine 374556-00-0P, N-[3-Chloro-5-[4H-indeno[2,1-d][1,3]thiazol-2-ylamino]phenyl]benzamidine 374556-01-1P, [3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl](6-phenylpyrimidin-4-yl)amine 374556-02-2P, [3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl][6-(thiophen-2-yl)pyrimidin-4-yl]amine 374556-03-3P, [3-(4,5-Dimethylimidazol-1-yl)phenyl][6-(thiophen-2-yl)pyrimidin-4-yl]amine 374556-04-4P, (6-Benzylpyridazin-3-yl)[3-(2,3-dimethyl-3H-imidazol-4-yl)phenyl]amine 374556-05-5P, [5,6-Dihydrobenzo[h]quinazolin-2-yl][3-(2,3-dimethyl-3H-imidazol-4-yl)phenyl]amine 374556-06-6P, [3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl]-[7-methoxy-5,6-dihydrobenzo[h]quinazolin-2-yl]amine 374556-08-8P 374556-09-9P, [3-(Imidazol-1-yl)phenyl]-[7-methoxy-5,6-dihydrobenzo[h]quinazolin-2-yl]amine 374556-10-2P, [3-(4,5-Dimethylimidazol-1-yl)phenyl]-[9-methoxy-5,6-dihydrobenzo[h]quinazolin-4-yl]amine 374556-11-3P, [9-Methoxy-5,6-dihydrobenzo[h]quinazolin-4-yl][3-(4-methylimidazol-1-yl)phenyl]amine 374556-12-4P, [3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl]-[9-methoxy-5,6-dihydrobenzo[h]quinazolin-4-yl]amine 374556-13-5P, N-[3-(1H-Imidazol-1-yl)phenyl]-9-methyl-4,5-dihydro[1]benzoxepino[5,4-c]isoxazol-3-amine 374556-15-7P 374556-16-8P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-2-amine 374556-17-9P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-9H-indeno[2,1-d]pyrimidin-2-amine 374556-18-0P 374556-19-1P 374556-20-4P, N-[3-(Imidazol-1-yl)phenyl]-N-[5-(pyrrol-1-yl)pyridin-2-yl]amine 374556-21-5P 374556-22-6P, N-[3-Chloro-5-[(6-fluorobenzo[d]isoxazol-3-yl)amino]phenyl]benzamidine 374556-23-7P, [3-(4,5-Dimethylimidazol-1-yl)phenyl][5-(thiophen-3-yl)isoquinolin-1-yl]amine 374556-24-8P, [3-(4-Methylimidazol-1-yl)phenyl][5-(thiophen-3-yl)isoquinolin-1-yl]amine 374556-25-9P, (6-Chlorobenzothiazol-2-yl)[3-(4,5-dimethylimidazol-1-yl)phenyl]amine 374556-26-0P, N-[3-Chloro-5-[(6-chlorobenzothiazol-2-yl)amino]phenyl]benzamidine 374556-27-1P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-8-(trifluoromethyl)-4-quinazolinamine 374556-28-2P, N-[3-(4,5-Dimethyl-1H-imidazol-1-yl)phenyl]-8-(trifluoromethyl)-4-quinazolinamine 374556-29-3P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-7-(trifluoromethyl)-4-quinazolinamine 374556-30-6P, N-[3-(4,5-Dimethyl-1H-imidazol-1-yl)phenyl]-7-(trifluoromethyl)-4-quinazolinamine 374556-31-7P 374556-32-8P 374556-33-9P 374556-34-0P 374556-35-1P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-1,2-benzo[d]isoxazol-3-amine 374556-37-3P, 7-Bromo-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-1,2-benzo[d]isoxazol-3-amine 374556-38-4P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-7-(2-thienyl)-1,2-benzo[d]isoxazol-3-amine 374556-39-5P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-7-(3-thienyl)-1,2-benzo[d]isoxazol-3-amine 374556-40-8P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-7-(4-fluorophenyl)-1,2-benzo[d]isoxazol-3-amine 374556-41-9P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]imidazo[1,5-a]pyridin-3-amine 374556-42-0P, 8-Chloro-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-6-(trifluoromethyl)imidazo[1,5-a]pyridin-3-amine 374556-43-1P 374556-44-2P, 7-Bromo-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-1H-indazol-3-amine 374556-46-4P, N-[3-(4-Methyl-1H-imidazol-1-yl)phenyl]-8-(2-thienyl)-4-quinazolinamine 374556-47-5P, N-[3-(1,2-Dimethyl-1H-

imidazol-5-yl)phenyl]-8-(2-thienyl)-4-quinazolinamine 374556-48-6P, N-[3-(4,5-Dimethyl-1H-imidazol-1-yl)phenyl]-8-(2-thienyl)-4-quinazolinamine 374556-50-0P, N-[3-(3-Methyl-1H-1,2,4-triazol-1-yl)phenyl]-8-(2-thienyl)-4-quinazolinamine 374556-51-1P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-4-(4-fluorobenzyl)-1-phthalazinamine 374556-52-2P, 4-Benzyl-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-1-phthalazinamine 374556-53-3P, 4-Benzyl-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-1-isoquinolinamine 374556-54-4P, 4-Chloro-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-1-phthalazinamine 374556-55-5P 374556-56-6P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-4-phenoxy-1-phthalazinamine 374556-57-7P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-4-(2-thienylmethyl)-1-isoquinolinamine 374556-58-8P, N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-8-(3-thienyl)-4-quinazolinamine 374556-59-9P, N-[3-(4,5-Dimethyl-1H-imidazol-1-yl)phenyl]-8-(3-thienyl)-4-quinazolinamine 374556-61-3P, N-[3-(4,5-Dimethyl-1H-imidazol-1-yl)phenyl]-9-fluoro-5,6-dihydrobenzo[h]quinazolin-4-amine 374556-62-4P, 9-Fluoro-N-[3-(4-methyl-1H-imidazol-1-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374556-63-5P, 9-Fluoro-N-[3-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374556-64-6P, 9-Fluoro-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374556-65-7P, 9-Fluoro-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyphenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 374556-67-9P 374556-68-0P, N-[3-(4-Methyl-1H-imidazol-1-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine hydrochloride 374556-69-1P, N-[3-(4-Methyl-1H-imidazol-1-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine dihydrochloride 374556-70-4P 374556-71-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT 50-67-9, 5-HT, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT 24464-35-5P, 5-Phenylisoquinoline 374554-43-5P, 3-Bromo-2-fluoro-N-(3-nitrophenyl)benzamide
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

IT 70-11-1, 2-Bromo-1-phenylethanone 83-33-0, 1-Indanone 98-03-3, 2-Thiophenecarboxaldehyde 98-80-6, Phenylboronic acid 99-09-2, 3-Nitroaniline 108-36-1, 1,3-Dibromobenzene 108-45-2, 1,3-Phenylenediamine, reactions 119-65-3, Isoquinoline 462-08-8, 3-Aminopyridine 502-42-1, Cycloheptanone 532-55-8, N-Benzoyl isothiocyanate 536-38-9, 2-Bromo-1-(4-chlorophenyl)ethanone 575-61-1, Benzal phthalide 696-59-3, 2,5-Dimethoxytetrahydrofuran 1193-21-1, 4,6-Dichloropyrimidine 1468-84-4, 5,6-Dihydro-1-benzothiophene-7(4H)-one 1532-97-4, 4-Bromoisoquinoline 1573-92-8, 9-Fluorenone-1-carboxylic acid 1739-84-0, 1,2-Dimethylimidazole 1765-93-1, 4-Fluorophenylboronic acid 1849-02-1, 2-Chloro-1-methyl-1H-benzimidazole 2840-44-0, 7-Fluoro-3,4-dihydro-1(2H)-naphthalenone 3529-82-6, 3-Nitrophenyl isothiocyanate 3622-23-9, 2,6-Dichlorobenzothiazole 3731-51-9, 2-(Aminomethyl)pyridine 4548-45-2, 2-Chloro-5-nitropyridine 4637-24-5 4752-10-7, 1,4-Dichlorophthalazine 4857-06-1, 2-Chloro-1H-benzimidazole 4887-95-0, 2,6-Dichlorobenzimidazole 5000-66-8, 2-Bromo-1-(2-chlorophenyl)ethanone 6160-65-2, 1,1'-Thiocarbonyldiimidazole 6165-68-0, Thiophene-2-boronic acid 6165-69-1, 3-Thiopheneboronic acid 6932-80-5, 1-Chloroindan-2-one 10166-05-9, 4-Benzylisoquinoline

13331-27-6, 3-Nitrophenylboronic acid 13414-95-4, 6,7-Dihydro-1-benzothiophene-4(5H)-one 16263-52-8, 3-Chlorobenzo[d]isoxazole 16499-58-4, 7-(Trifluoromethyl)-4(3H)-quinazolinone 16499-59-5, 8-(Trifluoromethyl)-4(3H)-quinazolinone 16927-13-2, Bromophenylacetaldehyde 19493-44-8, 1-Chloroisoquinoline 20780-78-3, 7-Iodo-1H-indole-2,3-dione 32673-41-9, 1H-Imidazol-4-ylmethanol hydrochloride 33786-89-9, 5-Chloro-1,3-benzenediamine 34773-02-9, 2-Dimethylaminomethylene-3,4-dihydro-2H-naphthalen-1-one 34784-04-8, 5-Bromoisoquinoline 41011-01-2, 2-Bromo-1-(3-chlorophenyl)ethanone 41981-24-2, Methyl thiobenzimidate hydroiodide 57711-36-1, 4-Chloro-5,6-dihydrobenzo[h]quinazoline 57731-17-6, 2-Bromo-1-(5-chlorothiophen-2-yl)ethanone 59918-64-8, Thiophene-2-carboximidothioic acid methyl ester hydroiodide 60906-59-4, 3-Benzyl-6-chloropyridazine 69491-59-4, 3-(Pyrimidin-5-yl)phenylamine 81115-20-0, 1-Chloro-3,4-dihydro-1H-naphthalen-2-one 93500-88-0, 5-Oxo-2,3,4,5-tetrahydrobenzo[b]oxepine-4-carbonitrile 111841-05-5, 2-Bromo-1-(5-chloro-2-methoxyphenyl)ethanone 112677-67-5, 3-(Imidazol-1-yl)aniline 115525-89-8 120072-87-9, 7-Methoxy-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid methyl ester 120359-17-3, 4-(4-Fluorobenzyl)-1(2H)-phthalazinone 138830-48-5, 3-(4-Methylimidazol-1-yl)phenylamine 145013-05-4 161957-56-8, 3-Bromo-2-fluorobenzoic acid 176032-78-3, 3-([1,2,4]Triazol-1-yl)phenylamine 179411-72-4, (3-Amino-5-chlorophenyl)carbamic acid tert-butyl ester 206551-41-9, Methyl 3-bromo-2-fluorobenzoate 208927-11-1, 3-(1-Methylimidazol-5-yl)aniline 209740-89-6, 2-Dimethylaminomethylene-5-methoxy-3,4-dihydro-2H-naphthalen-1-one 217197-60-9, Ethyl 7-methyl-5-oxo-2,3,4,5-tetrahydrobenz[1]oxepine-4-carboxylate 223671-26-9, 5-Phenylisoquinoline-2-oxide 251554-29-7, Ethyl 5-oxo-2,3,4,5-tetrahydro-1-benzoxepine-4-carboxylate 287382-70-1, 2-Amino-3-(2-thienyl)benzoic acid 333792-46-4, 3-(1,2-Dimethyl-1H-imidazol-5-yl)aniline 333793-14-9, 4-Methyl-3-(pyrimidin-5-yl)phenylamine 333793-36-5, 3-(4,5-Dimethylimidazol-1-yl)phenylamine 354764-40-2, 4-Fluorothiobenzimidic acid methyl ester hydroiodide 361548-80-3, 3-(1,2-Dimethyl-1H-imidazol-5-yl)-5-nitrophenyl methyl ether 361548-83-6, 3-Chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)aniline 361549-75-9 374554-26-4, N-(3-Aminobenzyl)carbamic acid benzyl ester 374554-41-3, 3-Bromo-2-fluorobenzoyl chloride 374554-44-6, 3-Bromo-2-fluoro-N-(3-nitrophenyl)benzimidoyl chloride 374554-54-8, 5-Amino-1-chloroisoquinoline 374554-89-9, 3-Chloro-6-fluorobenzo[d]isoxazole 374555-12-1 374555-82-5, 3-(Imidazol-1-yl)phenylthiourea 374555-94-9 374555-96-1, [3-(4,5-Dimethylimidazol-1-yl)phenyl]thiourea 374556-07-7, 2-Methylsulfinyl-7-methoxy-5,6-dihydrobenzo[h]quinazoline 374556-45-3, 4-Chloro-8-(2-thienyl)quinazoline 374556-49-7, 3-(3-Methyl-1H-1,2,4-triazol-1-yl)phenylamine 374556-60-2, 4-Chloro-9-fluoro-5,6-dihydrobenzo[h]quinazoline 384340-18-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:114996 CAPLUS
DN 134:157582
TI Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using nonsteroidal anti-inflammatory drugs and naturally occurring conotoxins
IN Meythaler, Jay M.; Peduzzi, Jean
PA UAB Research Foundation, USA
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010455	A1	20010215	WO 2000-US21893	20000810
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2379052	AA	20010215	CA 2000-2379052	20000810
	EP 1210100	A1	20020605	EP 2000-955437	20000810
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003520199	T2	20030702	JP 2001-514971	20000810
	NZ 517250	A	20041224	NZ 2000-517250	20000810
PRAI	US 1999-148068P	P	19990810		
	WO 2000-US21893	W	20000810		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT Drug delivery systems
(**prodrugs**; NSAID and/or conotoxin for treating traumatic brain and **spinal** cord injuries and other neurogenic conditions)

IT Blood vessel, disease
(vasculitis, **CNS**, neuronal injury from; NSAID and/or conotoxin for treating traumatic brain and spinal cord injuries and other neurogenic conditions)

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:754960 CAPLUS
DN 134:336242
TI Methylprednisolone suleptanate(Pharmacia Corp)
AU Paggiaro, Pierluigi
CS University of Pisa Fisiopatologia Respiratoria Ospedale di Cisanello, Pisa, 56100, Italy
SO Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2000), 1(1), 97-103
CODEN: COIDAZ
PB PharmaPress Ltd.
DT Journal; General Review
LA English
RE.CNT 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB A review with many refs. Methylprednisolone suleptanate (Promedrol) is a **prodrug** of methylprednisolone being developed by Pharmacia Corp (formerly Pharmacia & Upjohn) for the treatment of asthma. It has been approved for this indication in Switzerland and is awaiting registration in several other countries. Preliminary preclin. data indicated the potential use of methylprednisolone suleptanate for the i.v. treatment of immunol. disease. Its anti-inflammatory/bronchodilatory effect was demonstrated in mice and rats and in a guinea pig model. Animal models have also demonstrated the use of methylprednisolome suleptanate for the treatment of nephritis and hypotension. Efficacy and safety of pulse therapy Promedrol was demonstrated in a phase II trial using lupus nephritis patients. The recommended dose for pulse therapy is 400 mg equivalent/day i.v. Other studies in lupus patients have shown that doses of up to 1000 mg/day are well tolerated and pulse therapy with either 400 or 800 mg/day are efficacious in delaying the onset of **CNS** symptoms in SLE patients with organic brain disease. Preclin. studies are also taking place for the potential treatment of **spinal** cord injury. In Apr. 2000, Morgan Stanley Dean Witter estimated sales would be US $281 million

in 2003, rising to $277 million in 2004.

```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
VAR G1=P/O
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE


=> s l1 ful
FULL SEARCH INITIATED 14:52:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    18268 TO ITERATE

100.0% PROCESSED    18268 ITERATIONS                                 416 ANSWERS
SEARCH TIME: 00.00.01

L3           416 SEA SSS FUL L1
```

```
=> d l4
L4 HAS NO ANSWERS
L4                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS   9

STEREO ATTRIBUTES: NONE


=> search l4
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):l3
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 14:53:10 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -       12 TO ITERATE

100.0% PROCESSED       12 ITERATIONS                                  9 ANSWERS
SEARCH TIME: 00.00.01

L5             9 SEA SUB=L3 SSS FUL L4
```

```
=> s l5
L6          11 L5

=> d bib abs hitstr 1-11

L6   ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:513486  CAPLUS
DN   141:47362
TI   Pyridines for treating injured mammalian nerve tissue
IN   Borgens, Richard B.; Shi, Riyi; Byrn, Stephen R.; Smith, Daniel T.
PA   Purdue Research Foundation, USA
SO   PCT Int. Appl., 51 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2004052291        A2    20040624    WO 2003-US38834        20031205
     WO 2004052291        A3    20041014
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2508165           AA    20040624    CA 2003-2508165        20031205
     US 2004171587        A1    20040902    US 2003-730495         20031205
     EP 1567497           A2    20050831    EP 2003-796756         20031205
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2002-431637P      P     20021206
     WO 2003-US38834      W     20031205
OS   MARPAT 141:47362
AB   The invention provides novel pyridines, pharmaceutical compns. comprising
     such pyridines, and the use of such compns. in treating injured mammalian
     nerve tissue, including but not limited to an injured spinal cord in one
     embodiment, the compds., compns., and methods of the instant invention
     treat a mammalian nerve tissue injury by restoring action potential or
     nerve impulse conduction through a nerve tissue lesion.  Significantly, in
     vivo application of compds. of the instant invention established, on the
     basis of SSEP testing, that the compds. provide longer lasting effects at
     lower concns. than comparable treatment with the known agent
     4-aminopyridine (4 AP).
IT   21915-82-2P 97999-83-2P
     RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
        (pyridines for treating injured mammalian nerve tissue)
RN   21915-82-2  CAPLUS
CN   Phosphoramidic acid, 4-pyridinyl-, diphenyl ester (9CI)  (CA INDEX NAME)
```



RN 97999-83-2 CAPLUS
CN Phosphinic amide, P,P-diphenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:505547 CAPLUS
DN 123:198508
TI Phosphorylated adenine derivatives as potential synthons for antiviral agents
AU El Masri, Marwan; Berlin, K. Darrell
CS Dep. Chem., Oklahoma State Univ., Stillwater, OK, 74078, USA
SO Organic Preparations and Procedures International (1995), 27(2), 161-9
CODEN: OPPIAK; ISSN: 0030-4948
PB Organic Preparations and Procedures, Inc.
DT Journal
LA English
OS CASREACT 123:198508
GI



I

AB Phosphorylated adenines I [R = Cl; R1 = H, Me] were prepared from 9-(2-hydroxyethyl)adenine (II) by reaction with ClP(O)(OC6H4R1-4)2. I [R = Cl] were converted to I [R = N3, pyridylamino]. II was also converted to phosphate esters and phosphonates and phosphates of aniline and 4-aminopyridine were also prepared
IT **21915-82-2P 21966-23-4P 97999-83-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of phosphorylated aniline and aminopyridine)
RN 21915-82-2 CAPLUS
CN Phosphoramidic acid, 4-pyridinyl-, diphenyl ester (9CI) (CA INDEX NAME)



RN 21966-23-4 CAPLUS
CN Phosphoramidic acid, 4-pyridinyl-, bis(4-methylphenyl) ester (9CI) (CA INDEX NAME)



RN 97999-83-2 CAPLUS
CN Phosphinic amide, P,P-diphenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:594091 CAPLUS
DN 115:194091
TI Processing of silver halide color photographic materials
IN Kobayashi, Hidetoshi; Naruse, Hideaki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 41 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 02266351	A2	19901031	JP 1989-87755	19890406
PRAI JP 1989-87755		19890406		

AB Ag halide color photog. materials containing ≥1 type of color couplers together with ≥1 non-color-forming compds. selected from R1NHCOR2 (R1 = heterocyclyl, aryl; R2 = alkyl, aryl, heterocyclyl), R3NHSO2R4 (R3, R4 = R2; R3 and R4 can not be alkyl simultaneously), R5NHP(O)R6R7 (R5 = R2; R6, R7 = alkyl, aryl, alkoxy, aryloxy; R6R7 combination may form a

ring), and R8NHYNR9R10 (R8 = R1; R9, R10 = H, R1; Y = CO, SO2) are color developed in a benzyl-alc.-free color developer solution The use of amide compds. as the coupler solvents reduces Dmin without decreasing Dmax even in the absence of benzyl alc. in the developer.

IT **136664-74-9**
RL: USES (Uses)
(photog. coupler solvent)

RN 136664-74-9 CAPLUS

CN Phosphoramidic acid, 4-pyridinyl-, dibutyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:423604 CAPLUS

DN 101:23604

TI Phosphoric acid ester amides with some 2-aminoheterocyclic compounds

AU Tadzhitdinov, Z. B.; Makhamatkhanov, M. M.; Maksudov, N. Kh.

CS Tashk. Inst. Inzh. Irrig. Mekh. Sel'sk. Khoz., Tashkent, USSR

SO Deposited Doc. (1982), SPSTL 761 Khp-D82, 6 pp. Avail.: SPSTL

DT Report

LA Russian

AB (RO)2P(O)NHR1 [I, R = Ph, p-MeC6H4; R1 = (un)substituted 2-benzothiazolyl, 4-pyridyl, 2-benzoxazolyl, 2-thiazolyl] were prepared in 40.4-82.3 % yields by treating (RO)2P(O)Cl with R1NH2 in the presence of Et3N. I are potential pesticides (no data).

IT **21915-82-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 21915-82-2 CAPLUS

CN Phosphoramidic acid, 4-pyridinyl-, diphenyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1978:424451 CAPLUS

DN 89:24451

TI Searching for new potential pesticides for control of cotton-plant diseases

AU Maksudov, N. Kh.; Makhamatkhanov, M. M.; Aripov, A.; Seitkasymov, Zh.

CS Tashk. Inst. Inzh. Irrig. Mekh. Sel'sk. Khoz., Tashkent, USSR

SO Uzbekskii Khimicheskii Zhurnal (1978), (2), 70-9
CODEN: UZKZAC; ISSN: 0042-1707

DT Journal
LA Russian
GI



I



II



III

AB ClCH2P(X)RR1 (X = O, S; R, R1 = NHPh, substituted phenylamino, NEtPh, NHCH2Ph, morpholino) (12 compds., yield 40-80%), ClCH2CH2P(O)(OR)OCH2CH2Cl (R = Ph, substituted Ph, cyclohexyl, phthalimidomethyl) (10 compds., yield 40-90%), RR1P(O)CH2CH2SCN (R, R1 = OH, OCH2CH2Cl, substituted phenylamino, OCH2CH2SCN) (9 compds., yield 42-68%), I (X = O, S; n = 1, 2; R = Ph, ClCH2; R1 = Ph, Et2N, Bu2N, PhO, Cl3C6H2O; RR1P = heterocyclic) (12 compds., yield 33-90%), (BuS)2P(X)R (X = O, S; R = heterocyclic, 2-methylisothiourea residue) 7 compds., yield 26.5-57%), II (X = O, S; R = heterocyclic) (8 compds., yield 4.8-67.1%), III (R = H, Ph, PhCH2, substituted phenyl; R1 = H, Me, C6H4OH, Ph, furyl, p-MeOC6H4, 2,4-Cl2C6H3) (15 compds., yield 40-92.4%) were prepared as potential pesticides. Thus, reaction of ClCH2CH2P(O)RR1 with KSCN gave RR1P(O)CH2CH2SCN.

IT **66670-81-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as potential pesticides)

RN 66670-81-3 CAPLUS

CN Phosphinic amide, P-methyl-P-4-morpholinyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1977:140164 CAPLUS

DN 86:140164

TI Ester amides of β-chloroethylphosphonic acid

AU Maksudov, N. Kh.; Makhamatkhanov, M. M.; Bakhromova, M. M.; Yuldasheva, Kh.

CS Tashk. Inst. Inzh. Irrig. Mekh. Sel'sk. Khoz., Tashkent, USSR

SO Doklady Akademii Nauk UzSSR (1976), (9), 41-4
CODEN: DANUAO; ISSN: 0134-4307

DT Journal

LA Russian

AB Amidation of ClCH2CH2P(O)(OCH2CH2Cl)Cl, prepared from PCl3 and ethylene oxide via sucessive intermediates, P(OCH2CH2Cl)3 and ClCH2CH2P(O)(OCH2CH2Cl)2, with RNH2 gave 25-82% 18 ClCH2CH2P(O)(OCH2CH2Cl)R (R = PhNH, m-, p-toluidino, o-, p-ClC6H4NH, 2,4-Cl2C6H3NH, 1,3-Me2C6H3NH, o-, p-anisidino, p-BrC6H4NH, 7-methyl-2-benzothiazolylamino, 1-benzimidazolyl, piperidino, PhEtN, 2-Me-3-O2NC6H3NH, phthalimido, pyridin-4-ylamino, indolyl).

IT **61293-67-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 61293-67-2 CAPLUS

CN Phosphonamidic acid, P-(2-chloroethyl)-N-4-pyridinyl-, 2-chloroethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1977:16610 CAPLUS

DN 86:16610

TI Some results of studies on the synthesis of and search for new chemical preparations to control cotton plant diseases

AU Maksudov, N. Kh.

CS Tashk. Inst. Inzh. Irrig. Mekh. Sel'sk. Khoz., Tashkent, USSR

SO Uzbekskii Khimicheskii Zhurnal (1976), (3), 39-53
CODEN: UZKZAC

DT Journal

LA Russian

GI



I



II



III



IV

AB RP(O)(CH2CH2Cl)OCH2CH2Cl (R = substituted anilino, benzotriazolyl, benzimidazolyl, piperidyl, phthalimido, indolyl), I (R = Ph, p-tolyl, p-EtO2CC6H4, o-O2NC6H4, o-MeOC6H4), RC6H4NR2CH2CH(OH)R1 (R = H, o-, m-, p-Me, o-, m-, p-MeO, o-, m-, p-Cl, m-CF3, R1 = H, Me, MeOCH2, R2 = COCHCl2, substituted phenylcarbamoyl, acetyl, PhSO2), II (R = H, Me, Br, R1 = 3,4-Cl2C6H3, 3-F3CC6H4, 4-ClC6H4, 4-MeOC6H4, 3-O2NC6H4), RNHCOCH:CHCO2H (R = substituted phenyl, 2-thiazolyl, 2-pyridyl), III (R = substituted phenyl), IV (R = H, NO2, Br, R1 = alkenyl, 2-furylvinyl, vinyl, 1-propenyl, chloromethyl, isopropenyl), Et2NCS2R (R = alkenyl, alkyl, Ph, phenylcarbamoylmethyl), and RN:NR1 (R = 2,6-diamino-3-pyridyl, 2,4-diaminophenyl, histidyl, R1 = pyridyl, quinolyl, substituted phenyl)

(156 compds.), useful in control of cotton plant diseases (no data), were prepared by previously published syntheses.

IT **61293-67-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 61293-67-2 CAPLUS
CN Phosphonamidic acid, P-(2-chloroethyl)-N-4-pyridinyl-, 2-chloroethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1974:413610 CAPLUS
DN 81:13610
TI Phosphorylation of guanidines and aminopyridines
AU Grapov, A. F.; Razvodovskaya, L. V.; Kiselev, L. A.; Mel'nikov, N. N.
CS Vses. Nauchno-Issled. Inst. Khim. Sredstv Zashch. Rast., Moscow, USSR
SO Zhurnal Obshchei Khimii (1974), 44(3), 533-8
CODEN: ZOKHA4; ISSN: 0044-460X
DT Journal
LA Russian
AB MeP(X)RN:CR1R2 (R = EtO, p-ClC6H4O, 2,4-Cl2-C6H3O, Et2N; R1 = Me2N, H; R2 = m-ClC6H4NH, H; X = O, S) were prepared in 24-89% yields by treatment of MeP(X)RCl with an appropriate guanidine. Similarly 16-72% MeP(X)-RNHR1 (R = p-ClC6H4O, EtO, PhO, Et2N, 2,4,5-Cl3C6H2O; R1 = 2-pyridyl, 4-pyridyl; X = S, O) were obtained.

IT **52726-65-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52726-65-5 CAPLUS
CN Phosphonamidic acid, P-methyl-N-4-pyridinyl-, phenyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1972:153695 CAPLUS
DN 76:153695
TI 3- and 4-Pyridylamidophosphoric bis(ethylenimides)
AU Sazonov, N. V.; Safonova, T. S.; Minakova, S. M.; Chernov, V. A.
CS Vses. Nauchno-Issled. Khim.-Farm. Inst. im. Ordzhonikidze, Moscow, USSR
SO Khimiko-Farmatsevticheskii Zhurnal (1972), 6(3), 18-21

CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
AB 2,6- and 2,5-Dichloro-3-aminopyridine were converted to the corresponding 3-pyridylamidophosphoric bis(ethylenimides) by successive treatment with PCl5, anhydrous HCO2H, and ethylenimine containing Et3N. Nine substituted 4-pyridylamido-phosphoric bis(ethylenimides) were prepared analogously.
IT **35981-56-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 35981-56-7 CAPLUS
CN Phosphinic amide, P,P-bis(1-aziridinyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1969:87504 CAPLUS
DN 70:87504
TI Amidophosphates of the pyridine series
AU Dregval, G. F.; Martynyuk, A. P.; Kovalenko, N. V.
CS Donets. Filial Vses. Nauch.-Issled Inst. Khim. Reaktiv. Osobo Chist. Khim. Veshch., Donetsk, USSR
SO Khim. Geterotsikl. Soedin., Sb. 1: Azotsoderzhashchie Geterotsikly (1967), 236-9. Editor(s): Hillers, S. Publisher: Izd. "Zinatne", Riga, USSR.
CODEN: 20NNA2
DT Conference
LA Russian
GI For diagram(s), see printed CA Issue.
AB 2-Aminopyridine (I) and 4-aminopyridine (II) underwent condensation with (ArO)2P(X)Cl (III) in the presence of Et3N to give amidophosphates IV and V, resp. Reaction of 2 moles I with 1 mole (RO)P(X)Cl2 (VI) gave amidophosphates VII. No attack on the ring N occurred. To an ice-cold, stirred solution of 0.1 mole I and 0.1 mole Et3N in 40 ml. C6H6 was added 0.1 mole III in 15 ml. C6H6. The mixture was heated on the steam bath 2.5 hrs. to give the following IV (Ar, X, % yield, and m.p. given): Ph, O, 62, 145-6°; Ph, S, 32, 103-4°; p-MeC6H4, O, 46, 169-71°; p-MeC6H4, S, 61, 128-9°. To a stirred suspension of 0.1 mole II and 0.1 mole Et3N in 30 ml. PhMe was added 0.1 mole III in 20 ml. PhMe. The mixture was refluxed 3 hrs. to give the following V (Ar, X, % yield, and m.p. given): Ph, O, 76, 190-1°; Ph, S, 70, 151-2°; p-MeC6H4, O, 37, 215-16°. To a stirred, cooled solution of 0.2 mole I and 0.2 mole Et3N in 30 ml. PhMe was added 0.1 mole VI in 15-20 ml. PhMe, and the mixture was heated on the steam bath 2 hrs. to give the following VII (R, X, % yield, and m.p. given): PhO, O, 66, 192-3°; PhO, S, 60, 171-2°; p-MeC6H4, O, 89, 168-9° (VIII); p-MeC6H4O, S, 33, 170-2°; Ph, O, 38, 212-14°. To a solution of 0.1 mole I and 0.2 mole Et3N in 20 ml. PhMe was added a solution of 0.1 mole

(p-MeC6H4O)P(O)Cl2 in 15 ml. PhMe, and the mixture was heated on the steam bath for 2 hrs. to give 32% VIII.

IT **21915-82-2P 21966-23-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 21915-82-2 CAPLUS
CN Phosphoramidic acid, 4-pyridinyl-, diphenyl ester (9CI) (CA INDEX NAME)



RN 21966-23-4 CAPLUS
CN Phosphoramidic acid, 4-pyridinyl-, bis(4-methylphenyl) ester (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1963:409108 CAPLUS
DN 59:9108
OREF 59:1677a-d
TI Phosphoric acid amides
AU Gutmann, V.; Moertl, G.; Utvary, K.
CS Tech. Hochschule, Vienna
SO Monatshefte fuer Chemie (1962), 93, 1114-16
CODEN: MOCMB7; ISSN: 0026-9247
DT Journal
LA Unavailable
OS CASREACT 59:9108
AB Primary and secondary amines with diphenylphosphorus2POCl (I), with a tertiary amine, C5H5N, or the applied amine itself in excess as acid acceptor gave new amides which were insol. in H2O and could therefore be easily separated from by-products. I was prepared by the method of Gefter (CA 52, 19999d). The amine was carefully dried and reaction carried out in CCl4 over P2O5 by dropping I into excess of the dissolved amine with exclusion of atmospheric moisture. For the n-alkylamide, n-alkylamine was dissolved in CCl4, I added dropwise, the alkylammonium chloride filtered off, CCl4 distilled, the remaining oily product shaken with dilute K2CO3 solution, and the amide crystallized from Et2O. For the diethylamide, after removal of CCl4, the residue was dissolved in EtOH and crystallized at -10°. The isopropylamide was crystallized at lower temperature tert-Butylamide was crystallized from

Et2O. Anilide, benzylamide, cyclohexylamide, N-methylanilide, o-, m-, and p-toluidides, m-, and p-chloroanilides, and α, and β-naphthylamides were crystallized from hot EtOH by cooling to -6°. For the diphenylamide the residue was shaken with dilute NaOH, washed with H2O, and crystallized from EtOH. For 2-, 3-, 4-aminopyridides pyridine was added as acceptor, and after distillation of solvent the oily product obtained was treated with H2O and crystallized from EtOH. The following diphenylphosphinamides, PH2P(O)R were prepared (R, m.p., % yield given): NEt2, 141-2°, 25; PrNH, 90-3°, 46; iso-PrNH, 146-8°, 53; BuNH, 93-5°, 56; tert-BuNH, 133-6°, 25; PhNH, 242-4°, 85; PH2N, 105-6°, 15; PhMeN, 116-18°, 82; 2-MeC6H4NH, 127-9°, 65; 3-MeC6H4NH, 250-50.5°, 87; 4-MeC6H4NH, 205-6° (sublimes 195°), 70; 3-ClC6H4NH, 252-3°, 65; 4-ClC6H4NH, 215-16°, 74; PhCH2NH, 111-12°, 87; α-C10H7-NH, 188-90°, 72; α-C10H7NH, 264-8°; 82; 2-NHC5H4N, 177-80°, 34; 3-NHC5H4N, 203-4°, 35; 4-NHC5H4N, 173-4°, 42; cyclo-C6H11NH, 197-7.5°, 82.

IT **97999-83-2**, Phosphinic amide, P,P-diphenyl-N-4-pyridyl- (preparation of)

RN 97999-83-2 CAPLUS

CN Phosphinic amide, P,P-diphenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:50:37 ON 09 MAR 2006)

FILE 'REGISTRY' ENTERED AT 14:50:41 ON 09 MAR 2006

L1 STRUC

L2 21 S L1

L3 416 S L1 FUL

L4 STRUC

L5 9 SEARCH L4 SSS SUB=L3 FUL

FILE 'CAPLUS' ENTERED AT 14:54:21 ON 09 MAR 2006

L6 11 S L5

=> s l6 and (nerv?(l)(damag? or inju?))

393161 NERV?

378651 DAMAG?

150907 INJU?

24021 NERV?(L)(DAMAG? OR INJU?)

L7 1 L6 AND (NERV?(L)(DAMAG? OR INJU?))

=> d bib abs hitstr

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:513486 CAPLUS

DN 141:47362

TI Pyridines for treating **injured** mammalian **nerve** tissue

IN Borgens, Richard B.; Shi, Riyi; Byrn, Stephen R.; Smith, Daniel T.

PA Purdue Research Foundation, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004052291	A2	20040624	WO 2003-US38834	20031205
WO 2004052291	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508165	AA	20040624	CA 2003-2508165	20031205
US 2004171587	A1	20040902	US 2003-730495	20031205
EP 1567497	A2	20050831	EP 2003-796756	20031205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2002-431637P	P	20021206		
WO 2003-US38834	W	20031205		

OS MARPAT 141:47362

AB The invention provides novel pyridines, pharmaceutical compns. comprising such pyridines, and the use of such compns. in treating **injured** mammalian **nerve** tissue, including but not limited to an **injured** spinal cord in one embodiment, the compds., compns., and methods of the instant invention treat a mammalian **nerve** tissue **injury** by restoring action potential or **nerve** impulse conduction through a **nerve** tissue lesion. Significantly, in vivo application of compds. of the instant invention established, on the basis of SSEP testing, that the compds. provide longer lasting effects at lower concns. than comparable treatment with the known agent 4-aminopyridine (4 AP).

IT **21915-82-2P 97999-83-2P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridines for treating **injured** mammalian **nerve** tissue)

RN 21915-82-2 CAPLUS
CN Phosphoramidic acid, 4-pyridinyl-, diphenyl ester (9CI) (CA INDEX NAME)



RN 97999-83-2 CAPLUS
CN Phosphinic amide, P,P-diphenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)


O
Ph
P
NH
Ph
N

```
=> d l14
L14 HAS NO ANSWERS
L14                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE


=> search l14
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):l3
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 15:00:17 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -      394 TO ITERATE

100.0% PROCESSED      394 ITERATIONS                          394 ANSWERS
SEARCH TIME: 00.00.01

L15          394 SEA SUB=L3 SSS FUL L14
```




```
ENTER (DIS), GRA, NOD, BON OR ?:end
L20  STRUCTURE CREATED

=> search l20
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):l3
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 15:02:51 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -       59 TO ITERATE

100.0% PROCESSED       59 ITERATIONS                              38 ANSWERS
SEARCH TIME: 00.00.01

L21          38 SEA SUB=L3 SSS FUL L20
```

```
=> s l21 and (hydroxyamin? or pyridinam?)
         22621 HYDROXYAMIN?
         27974 PYRIDINAM?
L22         15 L21 AND (HYDROXYAMIN? OR PYRIDINAM?)
```

AN 2004:220207 CAPLUS
DN 140:270868
TI Preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents
IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Knutson, Chad; Mckittrick, Brian; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon
PA Schering Corporation, USA; Pharmacopeia, Inc.
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022062	A1	20040318	WO 2003-US27564	20030903
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2497539	AA	20040318	CA 2003-2497539	20030903
	AU 2003265901	A1	20040329	AU 2003-265901	20030903
	US 2004102452	A1	20040527	US 2003-654163	20030903
	EP 1545533	A1	20050629	EP 2003-794594	20030903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500391	T2	20060105	JP 2004-534490	20030903
PRAI	US 2002-408182P	P	20020904		
	WO 2003-US27564	W	20030903		

OS MARPAT 140:270868
GI



I

AB The title compds. [I; Q = SO2NR6R7, CONR6R7, CO2R7; R2 = (un)substituted alkyl, alkynyl, alkynylalkyl, cycloalkyl, CF3, CO2R6, aryl, arylalkyl, heteroarylalkyl, heterocyclyl, etc., wherein aryl is optionally substituted; R3 = H, halogen, NR5R6, CONR5R6, CO2R4, each (un)substituted alkyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, etc.; R4 = H, halo, alkyl; R5 = H, alkyl; R6 = H, each (un)substituted alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; R7 = each (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R5 and R6 in the moiety -NR5R6, may be joined together to form an (un)substituted cycloalkyl or heterocyclyl] or pharmaceutically acceptable salts or solvates thereof are prepared In its many embodiments, the present invention also provides

methods of preparing such compds., pharmaceutical compns. containing one or more
such compds. I, methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with cyclin dependent kinase using such compds. I or pharmaceutical compns. The disease associated with cyclin dependent kinase is selected from the group consisting of; (1) cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; (2) leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; (3) acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia; (4) fibrosarcoma and rhabdomyosarcoma; (5) astrocytoma, neuroblastoma, glioma and schwannomas; and (6) melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma.

IT **674297-87-1**

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents for treating diseases, in particular various cancers, associated with cyclin dependent kinase)

RN 674297-87-1 CAPLUS

CN 4-Pyridinamine, N-[(chlorocarbonyl)oxy]-, 1-oxide (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 1998:208421 CAPLUS
DN 128:270729
TI Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
IN Slusher, Barbara S.; Jackson, Paul F.; Tays, Kevin L.; Maclin, Keith M.
PA Guilford Pharmaceuticals Inc., USA
SO PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9813044	A1	19980402	WO 1997-US14417	19970815
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5824662	A	19981020	US 1996-718703	19960927
	US 5795877	A	19980818	US 1996-775586	19961231
	US 5863536	A	19990126	US 1996-778733	19961231
	US 5962521	A	19991005	US 1997-825997	19970404
	US 5902817	A	19990511	US 1997-835572	19970409
	US 6054444	A	20000425	US 1997-842360	19970424
	US 6025344	A	20000215	US 1997-858985	19970527
	US 6046180	A	20000404	US 1997-863624	19970527
	US 6017903	A	20000125	US 1997-884479	19970627
	US 6004946	A	19991221	US 1997-889358	19970708
	ZA 9707086	A	19980630	ZA 1997-7086	19970808
	ZA 9707085	A	19990208	ZA 1997-7085	19970808
	ZA 9707089	A	19990323	ZA 1997-7089	19970808
	ZA 9707090	A	19990323	ZA 1997-7090	19970808
	CA 2264158	AA	19980402	CA 1997-2264158	19970815
	AU 9741518	A1	19980417	AU 1997-41518	19970815
	EP 949922	A1	19991020	EP 1997-939427	19970815
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 5985855	A	19991116	US 1997-974975	19971120
	CA 2285906	AA	19981015	CA 1998-2285906	19980402
	WO 9845256	A1	19981015	WO 1998-US6382	19980402
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9869451	A1	19981030	AU 1998-69451	19980402
	AU 742418	B2	20020103		
	EP 973731	A1	20000126	EP 1998-915209	19980402
	EP 973731	B1	20020828		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001519809	T2	20011023	JP 1998-542871	19980402
	AT 222889	E	20020915	AT 1998-915209	19980402
	WO 9845257	A1	19981015	WO 1998-US6583	19980403
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,				

KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9871002 A1 19981030 AU 1998-71002 19980403
EP 1019369 A1 20000719 EP 1998-917985 19980403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
JP 2001521512 T2 20011106 JP 1998-542911 19980403
WO 9847906 A1 19981029 WO 1998-US7522 19980413
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9869723 A1 19981113 AU 1998-69723 19980413
US 6288046 B1 20010911 US 1999-298866 19990426
US 6271245 B1 20010807 US 1999-322688 19990601
US 2001044459 A1 20011122 US 2001-880861 20010615
PRAI US 1996-718703 A 19960927
US 1996-775586 A 19961231
US 1996-778733 A 19961231
US 1997-825997 A 19970404
US 1997-835572 A 19970409
US 1997-842360 A 19970424
US 1997-858985 A 19970527
US 1997-863624 A 19970527
US 1997-884479 A 19970627
US 1996-665776 A2 19960617
WO 1997-US14417 W 19970815
WO 1998-US6382 W 19980402
WO 1998-US6583 W 19980403
WO 1998-US7522 W 19980413
US 1999-322688 A3 19990601
OS MARPAT 128:270729
GI



I

AB The present invention relates to a method of treating a glutamate abnormality and a method of effecting a neuronal activity in an animal using a NAALADase inhibitor I (R1 = H, C1-9 straight or branched alkyl, C2-9 straight or branched alkenyl, C3-8 cycloalkenyl, C5-7 cycloalkenyl and aryl, etc.; R2 = C1-9 straight or branched alkenyl, C3-8 cycloalkyl, C5-7 cycloalkenyl and aryl, etc.; X = O, organoamino; organomethylene), and a pharmaceutical composition comprising an effective amount of a NAALADase inhibitor for treating a glutamate abnormality and effecting a neuronal activity in an animal. Thus, reaction of Me O-benzylphosphinic acid (preparation given) with dibenzyl 2-methylenepentanedioate in the presence of Et3N/Me3SiCl in CH2Cl2 followed by treatment with Me3Al and Pd-catalyzed

hydrogenation gave title compound, 2-[(methylhydroxyphosphinyl)methyl]pentanedioic acid, MeP(O)(OH)CH2CH(CO2H)CH2CH2CO2H. The biol. activity of the compds. prepared is described and discussed in detail.

IT **205310-61-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of glutamate derived hydroxyphosphinylalkanoic acids and naaladase compns. and methods for treating glutamate abnormality and effecting neuronal activity in animals)

RN 205310-61-8 CAPLUS

CN Pentanedioic acid, 2-[2-(hydroxy-4-pyridinylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 1999:705213 CAPLUS
DN 131:317798
TI Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
IN Slusher, Barbara S.; Jackson, Paul F.; Tays, Kevin L.; Maclin, Keith M.
PA Guilford Pharmaceuticals Inc., USA
SO U.S., 58 pp., Cont.-in-part of U.S. 5,824,662.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5977090	A	19991102	US 1997-899319	19970723
	US 5824662	A	19981020	US 1996-718703	19960927
	US 5795877	A	19980818	US 1996-775586	19961231
	US 5863536	A	19990126	US 1996-778733	19961231
	US 5962521	A	19991005	US 1997-825997	19970404
	US 5902817	A	19990511	US 1997-835572	19970409
	US 6025344	A	20000215	US 1997-858985	19970527
	US 6046180	A	20000404	US 1997-863624	19970527
	US 6017903	A	20000125	US 1997-884479	19970627
	US 6004946	A	19991221	US 1997-889358	19970708
	ZA 9707086	A	19980630	ZA 1997-7086	19970808
	ZA 9707085	A	19990208	ZA 1997-7085	19970808
	ZA 9707089	A	19990323	ZA 1997-7089	19970808
	ZA 9707090	A	19990323	ZA 1997-7090	19970808
	US 5985855	A	19991116	US 1997-974975	19971120
	US 6071965	A	20000606	US 1997-2147	19971231
	CA 2285906	AA	19981015	CA 1998-2285906	19980402
	WO 9845256	A1	19981015	WO 1998-US6382	19980402
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9869451	A1	19981030	AU 1998-69451	19980402
	AU 742418	B2	20020103		
	EP 973731	A1	20000126	EP 1998-915209	19980402
	EP 973731	B1	20020828		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001519809	T2	20011023	JP 1998-542871	19980402
	AT 222889	E	20020915	AT 1998-915209	19980402
	WO 9845257	A1	19981015	WO 1998-US6583	19980403
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9871002	A1	19981030	AU 1998-71002	19980403
	EP 1019369	A1	20000719	EP 1998-917985	19980403
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001521512	T2	20011106	JP 1998-542911	19980403
	US 6271245	B1	20010807	US 1999-322688	19990601
	US 2001044459	A1	20011122	US 2001-880861	20010615

PRAI US 1996-718703 A2 19960927
US 1996-775586 A2 19961231
US 1996-778733 A2 19961231
US 1997-825997 A2 19970404
US 1997-835572 A2 19970409
US 1997-858985 A2 19970527
US 1997-863624 A2 19970527
US 1997-884479 A2 19970627
US 1996-665775 A2 19960617
US 1996-665776 A2 19960617
US 1997-842360 A2 19970424
US 1997-864545 A2 19970528
US 1997-899319 A2 19970723
US 1997-900194 A2 19970729
WO 1998-US6382 W 19980402
WO 1998-US6583 W 19980403
US 1999-322688 A3 19990601

OS MARPAT 131:317798

AB A pharmaceutical composition and a method for treating a compulsive disorder using a NAALADase inhibitor (Markush included) are provided.

IT **205310-61-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NAALADase inhibitor preparation, pharmaceutical compns., and methods of treating compulsive disorders)

RN 205310-61-8 CAPLUS

CN Pentanedioic acid, 2-[2-(hydroxy-4-pyridinylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT